CD38 and AL amyloidosis: The aforementioned improvements in survival in both MM and AL amyloidosis in the last decades have largely been the result of widespread adoption of so-called novel agents, including proteasome inhibitors, immunomodulatory agents [10,19], and the anti-CD38 monoclonal antibody daratumumab, the first immunotherapy to gain the approval of the Food and Drug Administration (FDA) for treatment of MM [20] and subsequently AL amyloidosis [21].